Swiss Medtech startup Pregnolia, which specializes in the early diagnosis of premature birth, raised CHF 4.2 million in a Series A financing round. investiere has backed the company since its Seed financing round in 2018 and contributed CHF 1.6 million to this round.

Premature births give rise to high annual costs for medical treatment and care. Most cases cannot be predicted by experienced gynecologists. According to the WHO, premature births are on the rise in most countries and are now the second most common cause of mortality in children aged below five. Pregnolia has developed a measurement and diagnostic tool that helps doctors to significantly better assess the risk of premature birth.

“In spite of the coronavirus crisis, we gained numerous new investors. The funding round that we just concluded allows us to take a big step forward towards becoming the de facto standard in diagnostics for premature births”, says Sabrina Badir, Founder and CEO.

Why we invested in Pregnolia

“Pregnancy monitoring is a billion-dollar market. The aim of the Pregnolia system is to be able to give an immediate recommendation for therapy thanks to its easy handling in the existing clinical workflow and its high diagnostic reliability, thereby providing “peace of mind” to gynecologists and pregnant women, a strong competitive advantage. The successful round of funding clearly shows investor confidence in the technology”, says Susanne Schorsch, Investment Manager at investiere.

To learn more about this startup, read our interview with the founder Sabrina Badir about the EU grant the company received and the birth of the first “Pregnolia baby” as well as the interview with Prof. Kristin Myers, a key opinion leader in pregnancy biomechanics.